Yahoo Web Search

Search results

1. • RYBREVANT® (amivantamab-vmjw) plus lazertinib is the only chemotherapy-free regimen showing longer...

     Morningstar· 5 days ago

     Investigational chemotherapy-free regimen of RYBREVANT® plus lazertinib addresses a significant unmet need as most patients with EGFR-mutated NSCLC have high-risk disease ...

2. • Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on...

     Morningstar· 4 days ago

     Separate & Distinct from HARMONi-2 Announcement, HARMONi-A Showed Clinically Meaningful and Statistically Significant Benefit: PFS Hazard Ratio of 0.46 For Subset of Patients Previously Receiving 3rd Generation EGFR-TKI: PFS Hazard Ratio of 0.48 5.

3. • 

     Perioperative Chemo Extends Survival in Resectable Esophageal Cancer

     MedPage Today· 3 days ago

     A perioperative regimen of four cycles of chemotherapy before and after surgery extended overall...

4. • First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related...

     Ram Page· 5 days ago

     Johnson & Johnson announced today first data from the Phase 3 PALOMA-3 study evaluating subcutaneous (SC) amivantamab combined with lazertinib in patients with locally advanced or metastatic ...

5. • 

     Dual Immunotherapy Improves Response Rates in Gynecologic Clear Cell Cancers

     MedPage Today· 2 days ago

     At a median follow-up of 11.3 months, the overall response rate (ORR) among the 30 patients who...

6. • 

     No Survival Advantage With Sacituzumab Over Chemo in Previously Treated NSCLC

     MedPage Today· 4 days ago

     Results are 'disappointing as we need better therapies in the refractory space,' expert says

7. • Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald

     Roanoke-Chowan News-Herald· 6 days ago

     Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment ...

8. • 

     'Practice Changing' Trial for Inoperable Locally Advanced NSCLC

     MedPage Today· 4 days ago

     EGFR testing now needed for all patients with stage III disease, experts say

9. • Small Business - The Andalusia Star-News | The Andalusia Star-News

     The Andalusia Star-News· 3 days ago

     Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant ...

10. • 

      Study Reveals Worse Clinical Outcomes in Breast Ca | Newswise

      Newswise· 7 days ago

      Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who...